Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Isabel García-Ríos"'
Autor:
Angel Calvo Tudela, María Jesús García Anaya, Salvador Segado Guillot, Nuria Martin Romero, María Jesús Lorca Ocón, José Antonio Medina Carmona, Jaime Gómez‐Millán, Isabel García Ríos
Publikováno v:
Cancer Medicine, Vol 13, Iss 13, Pp n/a-n/a (2024)
Abstract Background The ‘FAST‐forward’, study published in April 2020, demonstrated the effectiveness of an extremely hypofractionated radiotherapy schedule, delivering the total radiation dose in five sessions over the course of 1 week. We sha
Externí odkaz:
https://doaj.org/article/02309118320b4d06a5ef398bef05db7c
Autor:
Isabel García-Ríos, J. A. Medina, Rafael Ordóñez, María Jesús García-Anaya, Alicia Román, Ana Otero, Jaime Gómez-Millán, M. D. Toledo, Raquel Correa
Publikováno v:
HeadneckREFERENCES. 43(3)
Purpose To identify predictors of palliation for head and neck cancer treated with the "Hypo Trial" hypofractionated radiation therapy regimen in a clinical setting. Design/method We retrospectively assessed 106 consecutive patients with incurable ca
Autor:
Bella Pajares, Victoria Scholtz, Jose Miramon, Alfonso Sánchez-Muñoz, Jose Manuel Jurado, Elena Gallego, Elisabeth Pérez-Ruiz, Antonia Márquez, Concepcion Soler, Isabel García-Ríos, Emilio Alba, Begoña Jimenez, Nuria Ribelles, Manuel Molina, Maria Maíz
Publikováno v:
The Breast Journal. 17:32-38
The prognosis and need or not for adjuvant therapy in patients with small breast tumors (≤1cm N0) is the subject of controversy as regards the clinical benefit obtained, toxicity, and the economical costs generated. A retrospective analysis was mad
Autor:
Elisabeth Pérez-Ruiz, Begoña Jimenez, Isabel García-Ríos, Emilio Alba Conejo, Alfonso Sánchez-Muñoz, Nuria Ribelles, Antonia Márquez
Publikováno v:
Clinical and Translational Oncology. 11:643-650
Breast cancer is a heterogeneous disease characterised by a dysregulation of multiple pathways related to cell differentiation, cell cycle control, apoptosis, angiogenesis and development of metastasis. Acting against these pathways provides therapeu
Autor:
Ismael Herruzo Cabrera, Antonio Sacchetti de Passos, Juan José Bretón García, José Antonio Medina Carmona, Isabel García Ríos, Manuel Cobo Dolls, Isabel Sevilla García, Emilio Alba Conejo
Publikováno v:
Clinical and Translational Oncology. 6:81-85
Introduccion El uso de quimioterapia y radioterapia en el cancer microcitico de pulmon (SCLC) mejora el control local y la supervivencia.
Autor:
Ismael Herruzo Cabrera, Amadeo Wals Zurita, Raquel Delgado Rico, A. Álvarez, Alberto Domínguez Mayoral, Raquel Correa Generoso, J. Blasco, Jorge Contreras Martínez, Inmaculada Fortes de la Torre e Isabel García Ríos
Publikováno v:
Revista de Oncología. 5:336-340
Introduccion Se ha realizado un estudio observacional con objeto de evaluar efectividad, toxicidad y satisfaccion de pacientes tratados con fentanilo-TTS en un servicio de Oncologia radioterapica.
Autor:
María Paz Acuña, Joaquín Cabrera, Julia Bolívar Muñoz, María Ángeles Pérez Escutia, Pilar Samper Ots, Armando Loayza Villaroel, María Mar Sevillano, Eloisa Bayo, Concepción López Carrizosa, Ana María Pérez Casas, María Mar Pérez, Miguel Angel Dominguez, Maria J. Ortiz, Escarlata López, Albert Biete, Isabel García Ríos, Moisés Mira, Amalia Sotoca, Ismael Herruzo, Ana I. Alvarez, V. Macias, Francisco Andreu
Publikováno v:
Clinicaltranslational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 13(5)
Anemia is the most common haematological complication in cancer patients.Analysis of the incidence, prevalence and treatment of anemia in oncologic patients treated in Radiation Oncology Departments in Spain (ROD) and monitoring of the existing recom
Autor:
Alfonso, Sánchez-Muñoz, Elisabeth, Pérez-Ruiz, Jose Manuel, Jurado, Nuria, Ribelles, Antonia, Márquez, Jose, Miramón, Maria, Maíz, Bella, Pajares, Elena, Gallego, Victoria, Scholtz, Begona, Jiménez, Concepcion, Soler, Manuel, Molina, Isabel, García-Ríos, Emilio, Alba
Publikováno v:
The breast journal. 17(1)
The prognosis and need or not for adjuvant therapy in patients with small breast tumors (≤1cm N0) is the subject of controversy as regards the clinical benefit obtained, toxicity, and the economical costs generated. A retrospective analysis was mad